Drug Substrate and Reaction | %Activity Relative to Wild-Type | Reference | |||
---|---|---|---|---|---|
CYP2B6.4 K262R (rs2279343) | CYP2B6.5 R487C (rs3211371) | CYP2B6.6 Q172H, K262R (rs3745274, rs2279343) | CYP2B6.7 Q172H, K262R, R487C (rs3745274, rs2279343, rs3211371) | ||
Cyclophosphamide (hydroxylation) | 72.6 | n.d | 164 | n.d | Ariyoshi et al., 2011 |
69.6 | 52 | 140 | n.d | Raccor et al., 2011 | |
Artemether (demethylation) | 223 | 24.8 | 192 | 154 | Honda et al., 2011 |
Bupropion (hydroxylation) | 101 | 81 | 123 | n.d | Raccor et al., 2011 |
35 | 47 | 43 | 79 | Zang et al., 2011 | |
Efavirenz (hydroxylation) | 142 | n.d | 50 | n.d | Ariyoshi et al., 2011 |
96 | 138 | 20 | 156 | Zang et al., 2011 |
Wild-type activity = 100%; n.d., not determined; rs, reference SNP number.